Last reviewed · How we verify
DCV
DCV is a direct-acting antiviral agent that inhibits the hepatitis C virus NS5B RNA-dependent RNA polymerase, blocking viral replication.
DCV is a direct-acting antiviral agent that inhibits the hepatitis C virus NS5B RNA-dependent RNA polymerase, blocking viral replication. Used for Chronic hepatitis C virus infection (genotype 1-6) in combination with other direct-acting antivirals.
At a glance
| Generic name | DCV |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | NS5B polymerase inhibitor |
| Target | HCV NS5B RNA-dependent RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
DCV (daclatasvir) binds to the NS5B polymerase of hepatitis C virus, preventing the enzyme from synthesizing viral RNA. This direct inhibition of a non-structural viral protein stops the replication cycle of HCV. It is typically used in combination with other direct-acting antivirals to achieve sustained virologic response.
Approved indications
- Chronic hepatitis C virus infection (genotype 1-6) in combination with other direct-acting antivirals
Common side effects
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) (PHASE1)
- Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia (NA)
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 (PHASE2)
- Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs
- Development and Validation of a Driving Simulator for Evaluating the Residual Effects of Drugs on Driving Performance - Sensitivity Analysis Using Zopiclone As a Positive Control (NA)
- Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #2 (NA)
- Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1 (NA)
- Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #3 (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DCV CI brief — competitive landscape report
- DCV updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI